Bone minerals refer to the inorganic compound of the bone tissue that helps in strengthening the bones with its plate and globular structures. These are dynamic in living beings formed from carbonated hydroxyapatite and are continuously reabsorbed and build a new in the bone remodeling process. Bone mineral metabolism maintains a sufficient concentration of inorganic ions in blood serum irrespective of muscle tissue metabolic activities. Furthermore, Bone and mineral metabolism disorder is the term used to describe various conditions that make bones weak. Additionally, Progressive chronic kidney disease, especially end-stage renal disease (ESRD), is responsible for adverse changes in bone and mineral metabolism.
The rising prevalence of Chronic Kidney Diseases (CKD) and metabolic diseases along with the increasing ageing population and obese patients is supporting the market growth. The presence of local and multinational players with wide variety of product offerings that helps in boosting bone and mineral metabolism disorders treatment is additionally supporting the market value. The growing awareness about the management of bone and mineral metabolism disorders among healthcare professionals as well as increased access to diagnosis are additionally bolstering the market growth.
On the other side, high cost associated with the management of comorbidities, noncompliance with the treatment protocols, and side effects associated with drugs are some of the factors likely to hamper the market growth during the forecast timeframe from 2020 to 2027.
North America accounted for the maximum revenue share in the Bone and Mineral Disorders Market
In 2019, North America leading the bone and mineral disorders market with maximum share (%) in terms of revenue (US$ Mn). The presence of major players in the region along with the increasing number of elder population is supporting the regional market value. The increasing number of patients with chronic diseases is further supporting the regional market value. According to the national kidney foundation (NKF) estimates of 2019, 15% of US adults i.e. 37 million adults in the United States are estimated to have chronic kidney disease (CKD) and millions of others are at increased risk. Additionally, 1 in 2 people with very low kidney function who are not on dialysis do not know they have CKD.
Asia Pacific is projected to exhibit fastest growth over the forecast period from 2020 to 2027
Asia Pacific is projected to exhibit the fastest growth over the forecast period from 2020 to 2027. The developing economies of the region including China and India are contributing to the regional market value. The increasing investment by the major players in the healthcare sector due to increasing spending by customers is propelling the regional market value.
The players profiled in the report include AbbVie Inc., Amgen Inc., F. Hoffmann-La Roche Ltd, Merck & Co., Inc., Novartis AG, Sanofi, Shire, and Warner Chilcott LLC. The major bone and mineral disorders players were involved in strategic developments for escalating the profit share in regional as well as the global market. The major investments were announced in the bone and mineral disorders market for technological advancements along with the changing consumer lifestyle.
Market By Type of Disorder
Chronic kidney disease-associated mineral and bone disorders (CKD-MBD)
Paget’s disease of the bone
Market By Medication Type
Non-Calcium, Non-Metal-Based Binder
Vitamin D Analogs and Supplements
Calcium and Magnesium Supplements
Market By Distribution Channel
Market By Geography
Middle East & Africa